Heparin and its derivatives in the treatment of arterial thrombosis: a review

Autoři

DVOŘÁK Martin VLAŠÍN Michal DVOŘÁKOVÁ Martina RAUŠER Petr LEXMAULOVÁ Leona GREGOR Zdeněk STAFFA Robert

Rok publikování 2010
Druh Článek v odborném periodiku
Časopis / Zdroj Veterinární medicína
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
Obor Chirurgie včetně transplantologie
Klíčová slova coagulation; arterial thrombosis; standard heparin; low-molecular weight heparins
Popis Arterial occlusion due to thrombosis caused by ruptured atherosclerotic plaques has been recognized as a major cause of morbidity and mortality in western populations. Along with chronic heart failure it significantly decreases patient life expectancy. The major goal of treatment remains fast recanalization and acute reocclusion prevention. Direct (antithrombin-independent) thrombin inhibitors can be divided into two main categories: monovalent and bivalent, while antithrombin stimulators represent standard (unfractionated) heparin (UFH) and its depolymerizing products - low molecular weight heparins (LMWH's). Recently a shift to prophylaxis of thromboembolic disease has been advocated. Unlike standard heparin, low-molecular weight heparins do not affect the patient's general coagulation profile. Obviously, the difference in molecular weight results in different pharmacokinetic and pharmacodynamic properties of the agents.

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info